EUVIMEDEUVIMED entdecken
Crossref

Lifetime psychedelic use and opioid use disorder severity in a National Survey: the roles of psychedelic type and mental health

Sebastian Ehmann, Nathan M Hager, Paul S Regier, Grant Jones, John J B Allen

Addictive Behaviors · 2026

DOI: 10.1016/j.addbeh.2026.108652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Addictive Behaviors, 2026. Verfasst von Sebastian Ehmann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, University of Arizona, Tucson, AZ, USA; Meditation Research Program, Department of Psychiatry, Massachusetts General Hospit…. Hauptthemen laut MEDLINE: Hallucinogens, Opioid-Related Disorders, Mental Disorders. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Substance Abuse and Mental Health Services Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Opioid use disorder (OUD) remains a major public health crisis in the United States, with mental health disorders substantially increasing risk severity. Emerging evidence suggests psychedelics may relate to reduced OUD risk. This exploratory study examined associations between lifetime psychedelic use and OUD severity and tested whether these associations varied by mental health impairment. METHODS: Structural equation modeling of the cross-sectional 2023 U.S. National Survey on Drug Use and Health with multiple-group moderation (n = 45,133 adults). OUD severity was the primary outcome. Independent variables were two psychedelic factors derived from factor analysis: mescaline/peyote (Psychedelic_F1) and LSD/psilocybin/MDMA/DMT (Psychedelic_F2). Mental health impairment was modeled as a latent construct and used to define high vs. low impairment groups. Covariates included age, sex, and income. FINDINGS: Psychedelic_F1 associated with lower OUD severity (β = -0.34, p = 0.001), whereas Psychedelic_F2 associated with higher severity (β = 0.60, p < 0.001). Mental health impairment positively associated with OUD severity (β = 0.21, p < 0.001). Moderation analyses indicated Psychedelic_F1 related to lower OUD severity only in the high mental health impairment group (β = -0.15, p = 0.041), while the positive association for Psychedelic_F2 was attenuated among those with high impairment (β = 0.38, p < 0.001, vs. β = 0.48, p = 0.004). CONCLUSIONS: Psychedelic use patterns showed divergent associations with OUD severity. Mescaline/peyote use was linked to lower severity, whereas LSD/psilocybin/MDMA/DMT use was linked to higher severity, with effects differing by mental health impairment. Contextual and motivational factors underlying psychedelic use warrant further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensOpioid-Related DisordersMental DisordersHumansUnited StatesFemaleCross-Sectional StudiesAdultSeverity of Illness IndexMaleMiddle AgedYoung AdultHealth SurveysMental HealthAdolescent

Stichwörter der Autor:innen

Mental health impairmentMescalineNational Survey on Drug Use and HealthOpioid use disorderPeyotePsychedelics

Substanzen

Hallucinogens

Autor:innen und Institutionen

  • Department of Psychology, University of Arizona, Tucson, AZ, USA; Meditation Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: ehman…
  • Perelman School of Medicine, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Psychology, Harvard University, Cambridge, MA, USA.
  • Department of Psychology, University of Arizona, Tucson, AZ, USA.

Förderung

  • Substance Abuse and Mental Health Services Administration

Zitieren

APA

Ehmann, S., Hager, N. M., Regier, P. S., Jones, G., & Allen, J. J. B. (2026). Lifetime psychedelic use and opioid use disorder severity in a National Survey: the roles of psychedelic type and mental health. Addictive Behaviors. https://doi.org/10.1016/j.addbeh.2026.108652

Vancouver

Ehmann S, Hager NM, Regier PS, Jones G, Allen JJB. Lifetime psychedelic use and opioid use disorder severity in a National Survey: the roles of psychedelic type and mental health. Addictive Behaviors. 2026. doi:10.1016/j.addbeh.2026.108652

BibTeX
@article{Ehmann2026,
  author = {Ehmann, Sebastian and Hager, Nathan M and Regier, Paul S and Jones, Grant and Allen, John J B},
  title = {Lifetime psychedelic use and opioid use disorder severity in a National Survey: the roles of psychedelic type and mental health},
  journal = {Addictive Behaviors},
  year = {2026},
  doi = {10.1016/j.addbeh.2026.108652}
}
Kostenlos starten →